ERBB2 and breast carcinoma: These findings demonstrate the robustness of the HER receptor-ligand system that enables HER2+ breast cancer cells to survive loss of HER2 signaling without the need to invoke mutations in the target kinase or its downstream intermediaries, or the activation of redundant signaling pathways.